Evidence map›Paper›PMID 28270132›Full record

ArticleBMC cancer2017

Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.

Stine S Jensen, Stine A Petterson, Bo Halle, Charlotte Aaberg-Jessen, Bjarne W Kristensen

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Small Molecule Regulators of Ferroptosis.Advances in experimental medicine and biology · 2021
    Article
  9. Review
  10. Lysosomes in glioblastoma: pump up the volume.Cell cycle (Georgetown, Tex.) · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stine S JensenDepartment of Pathology, Odense University Hospital, Winsløwparken 15, 3. floor, 5000, Odense C, Denmark.
Stine A PettersonDepartment of Pathology, Odense University Hospital, Winsløwparken 15, 3. floor, 5000, Odense C, Denmark.
Bo HalleDepartment of Pathology, Odense University Hospital, Winsløwparken 15, 3. floor, 5000, Odense C, Denmark.
Charlotte Aaberg-JessenDepartment of Pathology, Odense University Hospital, Winsløwparken 15, 3. floor, 5000, Odense C, Denmark.
Bjarne W KristensenDepartment of Pathology, Odense University Hospital, Winsløwparken 15, 3. floor, 5000, Odense C, Denmark. bjarne.winther.kristensen@rsyd.dk.
University of Southern Denmark · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresistant brain tumor-initiating cells combined with the invasive properties of the tumors is believed to be critical for treatment resistance. In the present study, the aim was to investigate the effect of a novel therapeutic strategy using the lysosomotropic detergent siramesine on glioblastomas.

methodsStandard glioma cell lines and patient-derived spheroids cultures with tumor-initiating stem-like cells were used to investigate effects of siramesine on proliferation and cell death. Responsible mechanisms were investigated by inhibitors of caspases and cathepsins. Effects of siramesine on migrating tumor cells were investigated by a flat surface migration assay and by implanting spheroids into organotypic rat brain slice cultures followed by confocal time-lapse imaging. Finally the effect of siramesine was investigated in an orthotopic mouse glioblastoma model. Results obtained in vitro and in vivo were confirmed by immunohistochemical staining of histological sections of spheroids, spheroids in brain slice cultures and tumors in mice brains.

resultsThe results showed that siramesine killed standard glioma cell lines in vitro, and loss of acridine orange staining suggested a compromised lysosomal membrane. Co-treatment of the cell lines with inhibitors of caspases and cathepsins suggested differential involvement in cell death. Siramesine caused tumor cell death and reduced secondary spheroid formation of patient-derived spheroid cultures. In the flat surface migration model siramesine caused tumor cell death and inhibited tumor cell migration. This could not be reproduced in the organotypic three dimensional spheroid-brain slice culture model or in the mice xenograft model.

conclusionsIn conclusion the in vitro results obtained with tumor cells and spheroids suggest a potential of lysosomal destabilizing drugs in killing glioblastoma cells, but siramesine was without effect in the organotypic spheroid-brain slice culture model and the in vivo xenograft model.

Indexed as

AnimalsCell DeathCell Line, TumorCell MovementDisease Models, AnimalGlioblastomaHumansIndolesLysosomesMiceNeoplasm Recurrence, LocalNeoplastic Stem CellsSpheroids, CellularSpiro CompoundsXenograft Model Antitumor AssaysIndolesLu 28-179Spiro CompoundsBrain slice culturesCancer stem cellGlioblastomaLysosomesSiramesineSpheroids

Identifiers

PMID28270132
PMCPMC5341392
OpenAlexW2594628416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.